% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • ozark580 ozark580 Nov 1, 2012 10:48 PM Flag

    Polish Doctor makes comments

    Polish doctor is using Prochymal to treat GvHD; read this:
    “Oporny gvHD no jest właśnie śmiertelny pacjenci ale jest niszczycielski dla, rodziny, przyjaciół i opiekunów które oglądają bezradnie" powiedzieli Joanne Kurtzberg, MD, głowa Pediatryczny szpika kostnego przeszczepu program dla Prochymal i główny śledczy, przy diuka uniwersytetem. ", ono nęka kogoś gdy choroba rozwija się," "osobiście widziałem Prochymal odwracać osłabiających skutki surowy gvHD w dużo mój pacjenci i teraz, po tym jak prawie dwie dekady badanie dane demonstruje zgodnie wysokich odpowiedzi tempa, silny zbawczy profil i ulepszający przetrwania poparcie, wyraźnie use Prochymal w zarządzaniu oporny gvHD."
    “The reluctant gvHD no is just deadly patients but is devastating for, family, friends and caregivers that they are watching helplessly, "said Joanne Kurtzberg, MD, head of the paediatric szpika marrow transplant program for Prochymal and principal investigators at Duke University. "it harassing someone when the disease develops," "personally I've seen Prochymal reverse debilitating effects of severe gvHD in a lot of my patients and now, after almost two decades of study data demonstrates according high response rate, strong safety profile and improving the survival of support, clearly use Prochymal in the management of recalcitrant gvHD."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • edimartino Nov 2, 2012 10:00 AM Flag

      Ozark you are very informed on this stock. Any ideas if we see a nice uptick based onn cc.

      • 1 Reply to edimartino
      • My best guess is that Ovation Sales are skyrocketing. All clues point in that direction

        Dr. Mills has done everything, but paint a picture for us. He has already told us that Ovation is taking a "significant" market share away from Medtronic's INFUSE product. INFUSE had nearly $800 million in Sales in 2011 and Medtronic's 2nd quarter report has already shown that their Sales have decreased by about $33 million (19%), due to competition and legal problems.

        I'm expecting a large increase in Ovation Sales in Osiris' 3rd to be released November 5th, Monday.

        I've said this many times...Osiris is a long term hold and I think it will be a 3 digit stock for those with patience!

        If you want a ride, you'll have to buy a ticket...but first, do your own Due Diligence.

        All above comments are my opinions.

    • Mariusz Pudzianowski would use it.

      Sentiment: Strong Buy

4.78-0.11(-2.25%)Sep 23 4:00 PMEDT